Infectious Disease Phase 3 Readout Calendar
Industry-sponsored infectious disease trials with primary completion in the next 12 months or last 12 months.
Data last updated July 17, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularInfectious DiseaseRespiratoryRare DiseaseOphthalmologyDermatologyMusculoskeletalRenalPain
20
Next 6 months
29
Next 12 months
26
Results posted
140
Phase 3 Infectious Disease
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 infectious disease trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What infectious disease trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 infectious disease trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which infectious disease trials have already read out?
The "recently read out" section shows Phase 3 infectious disease trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the Infectious Disease slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Infectious Disease landscape →
Recently read out & awaiting topline — Infectious Disease
· 17Phase 3 infectious disease trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Mundipharma Research Limited | Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation Asset: Rezafungin for Injection | Candidemia +9 | Completed | Q1 2026 2026-01-29 | Completed · awaiting
Updated 3mo ago
| NCT04368559 |
| F2G Biotech GmbH | Olorofim Aspergillus Infection Study Asset: Olorofim | Invasive Aspergillosis | Active Not Recruiting | Q4 2025 2025-11-18 | Completed · awaiting
Updated 6mo ago
| NCT05101187 |
| ModernaTX, Inc. | Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ���50 Years of Age Asset: mRNA-1083 | COVID-19 +1 | Completed | Q4 2025 2025-11-17 | Completed · awaiting
Updated 7mo ago
| NCT06694389 |
| GlaxoSmithKline | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1) Asset: Bepirovirsen | Chronic Hepatitis B +1 | Completed | Q4 2025 2025-11-11 | Completed · awaiting
Updated 7mo ago
| NCT05630807 |
| GlaxoSmithKline | Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2) Asset: Bepirovirsen | Chronic Hepatitis B +1 | Completed | Q4 2025 2025-11-03 | Completed · awaiting
Updated 7mo ago
| NCT05630820 |
| Gilead Sciences | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy Asset: Bictegravir | HIV-1-infection | Active Not Recruiting | Q4 2025 2025-10-27 | Completed · awaiting
Updated 8mo ago
| NCT06333808 |
| ModernaTX, Inc. | A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age Asset: mRNA-1273.214 | SARS-CoV-2 | Completed | Q4 2025 2025-10-20 | Completed · awaiting
Updated 8mo ago
| NCT05436834 |
| Merck Sharp & Dohme LLC | A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054) Asset: DOR/ISL | HIV Infection | Active Not Recruiting | Q4 2025 2025-10-16 | Completed · awaiting
Updated 7mo ago
| NCT05766501 |
| Merck Sharp & Dohme LLC | DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) Asset: DOR/ISL | HIV-1 Infection | Active Not Recruiting | Q4 2025 2025-10-13 | Completed · awaiting
Updated 9mo ago
| NCT05705349 |
| Pfizer | A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults Asset: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE | Respiratory Syncytial Virus (RSV) | Completed | Q3 2025 2025-09-30 | Completed · awaiting
Updated 8mo ago
| NCT06890416 |
| Gilead Sciences | Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Asset: Bictegravir | HIV-1-infection | Active Not Recruiting | Q3 2025 2025-09-29 | Completed · awaiting
Updated 9mo ago
| NCT05502341 |
| ViiV Healthcare | A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy Asset: DTG/3TC | HIV Infections | Completed | Q3 2025 2025-09-16 | Completed · awaiting
Updated 4mo ago
| NCT05917509 |
| Eurofarma Laboratorios S.A. | Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment Asset: Experimental drug (paracetamol 500mg / fexofenadine 60mg / phenylephrine 20mg) | Cold +1 | Completed | Q3 2025 2025-08-26 | Completed · awaiting
Updated 10mo ago
| NCT05118672 |
| ModernaTX, Inc. | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age Asset: mRNA-1010 | Seasonal Influenza | Completed | Q3 2025 2025-08-21 | Completed · awaiting
Updated 10mo ago
| NCT06602024 |
| ModernaTX, Inc. | A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age Asset: Placebo | Respiratory Syncytial Virus | Completed | Q3 2025 2025-07-28 | Completed · awaiting
Updated 11mo ago
| NCT05127434 |
| Zhuhai Trinomab Pharmaceutical Co.… | A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk Infants Asset: TNM001 | Respiratory Syncytial Virus Infections | Completed | Q3 2025 2025-07-27 | Completed · awaiting
Updated 4mo ago
| NCT06710925 |
| AstraZeneca | A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of Nirsevimab Asset: Nirsevimab | Respiratory Syncytial Virus Infections | Completed | Q3 2025 2025-07-24 | Read out | NCT06042049 |
Upcoming infectious disease readouts — next 12 months
· 29Industry Phase 3 infectious disease trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| BioNTech SE | A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children Asset: Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose | SARS-CoV-2 Virus +2 | Active Not Recruiting | Q3 2026 2026-07-23 (est.) | Estimated · fresh
Updated 3mo ago
| NCT05543616 |
| Novavax | A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine Asset: CIC Vaccine Co-formulated tNIV2 , SARSCoV-2 rS and Matrix-M Adjuvant | COVID-19 | Completed | Q3 2026 2026-07-26 (est.) | Estimated · aging
Updated 12mo ago
| NCT06291857 |
| ModernaTX, Inc. | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults Asset: mRNA-1345 | Respiratory Syncytial Virus | Active Not Recruiting | Q3 2026 2026-07-30 (est.) | Estimated · aging
Updated 11mo ago
| NCT06067230 |
| Pfizer | EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease Asset: nirmatrelvir | COVID-19 | Recruiting | Q3 2026 2026-07-30 (est.) | Estimated · aging
Updated 12mo ago
| NCT05261139 |
| BioNTech SE | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age Asset: BNT162b2 Vaccine | COVID-19 +1 | Active Not Recruiting | Q3 2026 2026-07-31 (est.) | Estimated · fresh
Updated 3mo ago
| NCT07300839 |
Unlock 24 more infectious disease readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.